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World AIDS Day is a good time to remind the world 
that the infection that dominated the news headlines 
for so much of the 1980 and 1990s but now rarely makes 
even the front page of International media, is still here. 
It is still killing more than 3000 people per day of whom 
more than 500 are children. Ebola has come and almost 
gone but all through that outbreak AIDS continued to kill 
many fold more than ever Ebola did.
There is no argument that serious inroads have been 
made into both the death toll and medical and social 
havoc wreaked by HIV compared to those early days. 
Massive investment has led to a larger number of new 
drugs being discovered and brought to market over a 
30 year period than has ever been the case for any human 
disease at any time. The number of new diagnoses of HIV 
infection and AIDS worldwide is declining year by year 
and we have learnt that this new approach to an infection 
which we cannot eradicate yet, that of making infected 
people less infectious, actually works. Pre exposure 
prophylaxis (PrEP), despite its detractors and the inbuilt 
problems with its use, drug sharing etc. is a truly viable 
component of reducing transmission and should be avail-
able to all high risk individuals including sex workers in 
the developing world. Recent results have even shown 
that drug resistance that had been much feared as a con-
sequence of PrEP has been extremely infrequent and that 
a strategy termed PrEP on demand in which antiretro-
viral drugs (ARVs) are taken only in anticipation of and 
following sexual relations works as well as daily doses of 
ARVs, thereby reducing both drug side effects and costs.
Meanwhile in the wealthier world we are confronted 
with an almost bewildering choice of therapeutic regimes 
amongst which it is possible to find something that suits 
virtually everyone. More remarkable still is the observa-
tion that patients with HIV not only do well, they actually 
may have a health advantage through the intensive man-
agement of all their other medical conditions. The CHIC 
study in the UK now shows that a 35 year old male newly 
diagnosed with HIV and a CD4 count of 200, if treated 
appropriately and achieving a CD4 count of 350 within 
a year, now has a potential lifespan to age 81 which is 
3 years longer than the average for an uninfected 35 year 
old. HIV infection teaches us many things and it has has 
shown that regular follow up, equivalent to comprehen-
sive primary care, really makes a difference—quite a mes-
sage for governments and health services everywhere.
World AIDS Day is thus a chance to look back and cel-
ebrate our successes in what has been arguably the most 
impressive medical revolution ever, where a once 100 % 
fatal infection can now be a chronic condition associated 
with a normal or even prolonged lifespan.
But, as alluded to in the opening paragraph, World 
AIDS Day is also a time to remind people that HIV has 
not gone away and in many parts of the world it is still 
the major cause of death, albeit often in concert with its 
lethal partner TB. People in the West may not fear the 
disease as much and the associated decline in stigma 
is welcome, but in rural Africa the infection rages on. 
Antiretroviral therapy has reached a huge proportion of 
this population but for many the logistics of attending a 
centre to gain access to treatment is still a significant bar-
rier; the inconsistency of drug supplies—often leading 
to a triple regime temporarily becoming a dual or even 
monotherapy until supplies resume, is a continual driver 
for the emergence of drug resistance. Access is still linked 
to enrolment onto drug trials in some places and in oth-
ers the fragility of ongoing funding, particularly since 
the withdrawal of PEPFAR and the reliance on the state 
and other charities, means that from 1 month to the next 
patients with HIV infection may not know for certain 
whether they will have reliable supplies of the life saving 
drugs which not only keep them healthy but also sup-
press their viral load, thereby reducing overall burden by 
making them less infectious.
2015 then is perhaps a watershed year. With a vac-
cine still as remote as ever, and even if one was shown 
to generate significant protection this year it would still 
be 5 years or more before it could be rolled out, we have 
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to find other approaches to eliminating the virus. To 
that end we are now seeing the start of trials of thera-
pies designed to eradicate HIV. These are aimed at the 
reservoir of latently infected cells containing virus that 
is untouched by current drugs. Our knowledge of the 
causes underlying HIV latency is growing and we are 
realizing the heterogeneity underlying this state. There is 
a long way to go before the so called ‘kick and kill’ strate-
gies are augmented by highly specific therapies designed 
to selectively wake up each and every latent HIV but at 
least we are starting. Switching on a virus that is ‘asleep’ 
and which relies on normal cellular silencing processes 
to stay that way, while not switching on cellular genes in 
a dangerous and unnecessary way, is never going to be 
easy but every journey starts with a single step. To quote 
Churchill ‘This is not the end, it is not even the beginning 
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